Fangzhou Inc. Introduces Otsuka's Potent Leukemia Drug Ponatinib Through Its Platform Fangzhou Inc. has launched Otsuka’s Ponatinib, a third-generation leukemia drug, enhancing treatment options for chronic myeloid leukemia patients.

Fangzhou Inc. Introduces Otsuka's Potent Leukemia Drug Ponatinib Through Its Platform #Fangzhou_Inc. #Ponatinib #Otsuka_Pharmaceutical

Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated.
#Ponatinix45mg #Ponatinib #IebPharma #AntiCancer #AntiViral
iebpharma.com/product/pona...

2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA:

1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib

#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm

Ponaxen 15mg (Ponatinib) | Worldwide Shipping Treatment of adult patients with T3151- positive CML or T3151-positive Ponaxen 15mg (Ponatinib) chromosome positive acute lymphoblastic leukemia.

The mechanism of action of Ponaxen 15mg revolves around its ability to inhibit the activity of certain enzymes called tyrosine kinases.
#Ponaxen15mg #Ponatinib #Medicine #Health #OnlineMedicine #MedicineStore #AntiCancer #LiverCancer
iebpharma.com/product/pona...

Important lessons from #FDA accelerated approval of #ponatinib about tension between medical need, patient safety: jama.jamanetwork.com/Mobile/article.aspx